Physician profile
William R Jacobs
NPI 1740320761
$674.67
in general payments reported to CMS, 2019-2025
14 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.68 · 2020: $17.56 · 2021: $134 · 2022: $48.80 · 2023: $156 · 2024: $86.75 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $196.74 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $145.07 | 2019-2024 | |
| Abbott Laboratories | $80.00 | 2021-2024 | Octrode |
| Amgen INC. | $61.64 | 2021-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $38.35 | 2019 | |
| Exact Sciences Corporation | $31.52 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $28.19 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.56 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.07 | 2023 | Keveyis |
| Depuy Synthes Sales INC. | $13.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.